CervoMed (NASDAQ:CRVO) Stock Rating Upgraded by Brookline Capital Management
Brookline Capital Management upgraded shares of CervoMed (NASDAQ:CRVO – Free Report) from a hold rating to a strong-buy rating in a report published on Tuesday,Zacks.com reports. Brookline Capital Management also issued estimates for CervoMed’s Q4 2024 earnings at ($0.70) EPS, FY2024 earnings at ($1.80) EPS, Q1 2025 earnings at ($0.48) EPS, Q2 2025 earnings at […]
